In relation to Anninga et al. Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomasJUDSON, Ian.European journal of cancer (1990). 2004, Vol 40, Num 7, pp 924-925, issn 0959-8049, 2 p.Article

Role of expert centres in the management of sarcomas - A UK perspectiveBENSON, Charlotte; JUDSON, Ian.European journal of cancer (1990). 2014, Vol 50, Num 11, pp 1951-1956, issn 0959-8049, 6 p.Article

Imatinib mesylateJUDSON, Ian; VAN OOSTEROM, Allan.Drugs (Basel). 2003, Vol 63, Num 5, pp 523-524, issn 0012-6667, 2 p.Article

Safety evaluation of trabectedin in treatment of soft-tissue sarcomasMARTIN-LIBERAL, Juan; JUDSON, Ian.Expert opinion on drug safety. 2013, Vol 12, Num 6, pp 905-911, issn 1474-0338, 7 p.Article

Neoadjuvant and adjuvant therapy for extremity soft tissue sarcomasSCURR, Michelle; JUDSON, Ian.Hematology/oncology clinics of North America. 2005, Vol 19, Num 3, issn 0889-8588, vi, 489-500 [13 p.]Article

New drugs in sarcomasMARTIN-LIBERAL, Juan; BENSON, Charlotte; JUDSON, Ian et al.Expert opinion on pharmacotherapy. 2014, Vol 15, Num 2, pp 221-229, issn 1465-6566, 9 p.Article

Mediastinal hemangioma: Successful treatment by alpha-2a interferon and postchemotherapy resectionKUMAR, Pankaj; JUDSON, Ian; NICHOLSON, Andrew G et al.Journal of thoracic and cardiovascular surgery. 2002, Vol 124, Num 2, pp 404-406, issn 0022-5223Article

Soft-tissue sarcomas in adultsCLARK, Matthew A; FISHER, Cyril; JUDSON, Ian et al.The New England journal of medicine. 2005, Vol 353, Num 7, pp 701-711, issn 0028-4793, 11 p.Article

Phase I Trial of Combretastatin A4 Phosphate (CA4P) in Combination with Bevacizumab in Patients with Advanced CancerNATHAN, Paul; ZWEIFEL, Martin; TAYLOR, N. Jane et al.Clinical cancer research (Print). 2012, Vol 18, Num 12, pp 3428-3439, issn 1078-0432, 12 p.Article

Clinical Benefit of New Targeted Agents in Phase I Trials in Patients with Advanced Colorectal CancerARKENAU, Hendrik-Tobias; BRUNETTO, Andre T; BARRIUSO, Jorge et al.Oncology. 2009, Vol 76, Num 3, pp 151-156, issn 0030-2414, 6 p.Article

Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and LymphomasRAY-COQUARD, Isabelle; CROPET, Claire; GUASTAILA, Jean-Paul et al.Cancer research (Chicago, Ill.). 2009, Vol 69, Num 13, pp 5383-5391, issn 0008-5472, 9 p.Article

Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid TumorsPLUMMER, Ruth; VIDAL, Laura; REID, Gregory K et al.Clinical cancer research (Print). 2009, Vol 15, Num 9, pp 3177-3183, issn 1078-0432, 7 p.Article

An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer modelsBANERJI, Udai; SAIN, Nivedita; JACKMAN, Ann L et al.Cancer chemotherapy and pharmacology. 2008, Vol 62, Num 5, pp 769-778, issn 0344-5704, 10 p.Article

Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft modelsBANERJI, Udai; WALTON, Michael; RAYNAUD, Florence et al.Clinical cancer research. 2005, Vol 11, Num 19, pp 7023-7032, issn 1078-0432, 10 p., 1Article

Tivantinib (ARQ 197), a Selective Inhibitor of MET, in Patients With Microphthalmia Transcription Factor―Associated Tumors: Results of a Multicenter Phase 2 TrialWAGNER, Andrew J; GOLDBERG, John M; DAVIS, Ian J et al.Cancer. 2012, Vol 118, Num 23, pp 5894-5902, issn 0008-543X, 9 p.Article

A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit: Unplanned admissions as an early indicator of patient attritionBRUNETTO, Andre T; JOO ERN ANG; JUDSON, Ian et al.European journal of cancer (1990). 2010, Vol 46, Num 15, pp 2739-2745, issn 0959-8049, 7 p.Article

90-Days mortality rate in patients treated within the context of a phase-I trial : How should we identify patients who should not go on trial?ARKENAU, Hendrik-Tobias; OLMOS, David; JOO ERN ANG et al.European journal of cancer (1990). 2008, Vol 44, Num 11, pp 1536-1540, issn 0959-8049, 5 p.Article

Identification of factors limiting patient recruitment into phase I trials : A study from the Royal Marsden HospitalKARAUASILIS, Vasilios; DIGUE, Laurence; ARKENAU, Tobias et al.European journal of cancer (1990). 2008, Vol 44, Num 7, pp 978-982, issn 0959-8049, 5 p.Article

A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedinGROSSO, Federica; D'INCALCI, Maurizio; SOTO-MATOS, Arturo et al.Cancer chemotherapy and pharmacology. 2012, Vol 69, Num 6, pp 1557-1565, issn 0344-5704, 9 p.Article

Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumorsAPPLETON, Kim; MACKAY, Helen J; TANG, Adrian et al.Journal of clinical oncology. 2007, Vol 25, Num 29, pp 4603-4609, issn 0732-183X, 7 p.Article

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumoursDEBIEC-RYCHTER, Maria; SCIOT, Raf; ZALCBERG, John et al.European journal of cancer (1990). 2006, Vol 42, Num 8, pp 1093-1103, issn 0959-8049, 11 p.Article

Phase I trial of ZD9331, a nonpolyglutamatable thymidylate synthase inhibitor, given as a 5-day continuous infusion to patients with refractory solid malignanciesREES, Charlotte; BEALE, P; TRIGO, Jose Manuel et al.Clinical cancer research. 2003, Vol 9, Num 6, pp 2049-2055, issn 1078-0432, 7 p.Article

Contribution of Granulocyte Colony-Stimulating Factor to the Acute Mobilization of Endothelial Precursor Cells by Vascular Disrupting AgentsSHAKED, Yuval; TANG, Terence; SMYTHE, Jon et al.Cancer research (Chicago, Ill.). 2009, Vol 69, Num 19, pp 7524-7528, issn 0008-5472, 5 p.Article

Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosisCONSTANTINIDOU, Anastasia; JONES, Robin L; SCURR, Michelle et al.European journal of cancer (1990). 2009, Vol 45, Num 17, pp 2930-2934, issn 0959-8049, 5 p.Article

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid TumorsO'DONNELL, Anne; FAIVRE, Sandrine; BROCK, Cathryn et al.Journal of clinical oncology. 2008, Vol 26, Num 10, pp 1588-1595, issn 0732-183X, 8 p.Article